Takeda Pharmaceutical Co. has entered into a definitive agreement to acquire ARIAD Pharmaceuticals for approximately $5.2 billion. The transaction is expected to close by the end of February 2017, subject to customary closing conditions. The acquisition brings two targeted therapies that will expand Takeda’s existing oncology portfolio. Brigatinib, an investigational drug product, has the potential to add a differentiated, global therapy in a genetically-defined subpopulation of non-small cel...